Page 104 - Reliance Industries

Value of India's top 100 brands up 2% in 2021; Tata Group most valuable

Among the brands that came on the top of the list include Tata Group, Reliance Industries, and Mahindra Group

Govt challenges Panna-Mukta field arbitration before English High Court

The government has challenged an arbitration award over a cost recovery dispute in the western offshore Panna-Mukta and Tapti oil and gas fields of Shell and Reliance Industries Ltd.

Reliance Foundation seeks nod to import J&J doses for its workforce

Reliance Foundation is the philanthropic arm of the Mukesh Ambani-led Reliance Industries

SoftBank Group may invest $700 mn in Flipkart after exiting firm in 2018

Techy conglomerate investing in Flipkart at a time when Reliance Industries and Tata are betting big on e-commerce as well.

Top Headlines: RBI likely to hold interest rates; Softbank to back Flipkart

Our top headlines on Friday track the latest developments

Amid pandemic, chairman Mukesh Ambani drew no salary in FY21: Reliance

In the previous fiscal year, he drew a Rs 15 cr salary from the company - the same as in the previous 11 years

Reliance Industries set for windfall gain from oil and gas vertical

According to Harsh Dole, vice-president of IIFL, the commercialisation of key gas discoveries of RIL are no less than a game changer

Reliance submits proposal for potential coronavirus drug Niclosamide

Reliance Industries Ltd's R&D arm has proposed the use of Niclosamide - the drug used to treat tapeworm infestation - for treating COVID-19 patients. Niclosamide, a drug on the World Health Organisation's list of essential medicines, has been used to treat tapeworm infestation for more than 50 years. The oral antiviral drug was also used to treat patients during the SARS outbreak of 2003-04. "The company submitted a proposal for the application of Niclosamide as a potential drug against COVID-19," the firm's latest annual report said. The drug regulator will now evaluate the proposal for public use. The company however did not say if it plans to manufacture the drug or would use it to treat COVID patients at hospitals run by the group. The Indian government has already given clearance for the Phase 2 clinical trials of Niclosamide in COVID-19 treatment in adult patients. The Reliance R&D (research and development) team is also working with various Council of Scientific & ..

Tapeworm drug, masks are part of Reliance's plan to tackle coronavirus

Reliance Industries is exploring use of a tapeworm drug, Niclosamide, as a cure for Covid-19, according to its annual report.

Reliance Industries rallies 15% in seven days, hits over 7-month high

The stock was up 2.2 per cent at Rs 2,250 on the BSE in intra-day trade on Thursday, trading close to its record high level of Rs 2,368.80 touched on September 16, 2020

RIL to provide financial support to families of employees who died of Covid

Reliance Industries has said that it will continue to provide salaries for five years to the nominee of employees who succumbed to the disease

Indices end flat for the second straight session; ITC skids post results

After dropping to a low of 51,450.58 in late afternoon trade, the BSE Sensex clawed back lost ground to finish 85.40 points or 0.16 per cent down at 51,849.48

Reliance Industries' balance sheet is strong, says Mukesh Ambani

Submits a proposal for use of niclosamide as potential Covid drug

Top headlines: SC pulls up Centre over vaccination; PVR Q4 net loss widens

Business Standard brings you the day's top headlines

Jio accelerating digital platforms, indigenously-developed 5G stack: RIL

Jio is accelerating the rollout of digital platforms and indigenously-developed next-generation 5G stack, Reliance Industries' annual report has said

Nomura remains overweight on India; Infosys, RIL, ICICI Bank among top bets

Going ahead, Nomura said, markets will focus more on corporate earnings rather than the broad economic growth in India

Better petchem prospects, low-cost Jio smartphone launch push RIL stock

Shares of Reliance Industries are up more than 9 per cent over two days to Rs 2,160.45

Nifty makes new record, Sensex near fresh peak; RIL rises over 3%

The benchmark Sensex ended the session at 51,937, a gain of 514 points or 1 per cent. The index is currently 217 points or 0.42 per cent below its previous closing high of 52,154, made on February 15

Street signs: Call date with RIL, Pair strategy for Axis, ICICI Bank & more

Prices of key raw materials, such as copper, steel and aluminium, are up between 20 and 40 per cent in one year

Healthy outlook: Jefferies maintains buy on RIL, cited demand upside

Jefferies maintained the 'buy' call on RIL with a target and Rs 2,580 or 30 per cent upside.